berberine has been researched along with Alloxan Diabetes in 133 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Erectile dysfunction rats were screened out through the apomorphine test and randomly divided into the diabetes mellitus and berberine groups, and these animals were administered berberine (200 mg/kg/day) and normal saline by gavage for 4 weeks." | 8.12 | Berberine ameliorates erectile dysfunction in rats with streptozotocin-induced diabetes mellitus through the attenuation of apoptosis by inhibiting the SPHK1/S1P/S1PR2 and MAPK pathways. ( Chen, Y; Cui, K; Lan, R; Li, R; Ling, L; Liu, J; Liu, K; Luan, Y; Rao, K; Ruan, Y; Song, J; Sun, T; Wang, S; Wang, T; Yuan, P, 2022) |
| "Berberine may slow the progression of prediabetes to T2DM in ZDF rats by improving GLP-2 secretion, intestinal permeability, and the structure of the gut microbiota." | 8.02 | Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. ( Jiang, Y; Kong, Y; Liu, H; Ren, H; Shan, C; Wang, J; Wang, S; Wang, Y; Yang, J; Yang, Y; Zheng, M, 2021) |
| "Dysregulated glucagon drives hyperfunction in hepatic glucose output, which is the main cause of persistent hyperglycemia in type 2 diabetes." | 7.96 | Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. ( Jiang, B; Jin, J; Liu, P; Sheng, L; Song, Y; Zhang, H; Zhong, Y; Zhou, H, 2020) |
| " Role of JAK2 in the Pathogenesis of Diabetic Erectile Dysfunction and an Intervention With Berberine." | 7.91 | Role of JAK2 in the Pathogenesis of Diabetic Erectile Dysfunction and an Intervention With Berberine. ( Jiang, H; Lan, R; Li, H; Liu, J; Song, J; Sun, T; Tang, Z; Wang, S; Wang, T; Ye, Z, 2019) |
| "The combination of resveratrol with glibenclamide may alleviate reperfusion-induced arrhythmias via an underlying mechanism not be only associated with the restoration of the protein expression of Kir6." | 7.91 | The protection of resveratrol and its combination with glibenclamide, but not berberine on the diabetic hearts against reperfusion-induced arrhythmias: the role of myocardial K ( Bozdogan, O; Eksioglu, D; Erim, F; Firat, T; Kaya, ST; Ozarslan, TO; Taskin, E; Yasar, S, 2019) |
| "Objective To explore the effect of berberine on cardiac fibrosis of diabetic rats by observing the expressions of serum transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF) , collagen type 1 (Col1) and collagen type 3 (Col3) in myocardial tissues of diabetic rats after berberine treatment." | 7.83 | [Berberine inhibits cardiac fibrosis of diabetic rats]. ( He, J; Liu, G; Lu, K; Shen, Y; Song, W, 2016) |
| "This study investigated the effects of berberine on amelioration of hyperglycemia and hyperlipidemia and the mechanism involved in high glucose and high fat diet-induced diabetic hamsters." | 7.81 | Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. ( Jin, J; Li, L; Li, P; Liu, C; Song, Y; Wang, Z; Wu, D; Xu, N; Zheng, X, 2015) |
| "The present study was designed to elucidate the potential mechanism underlying that berberine suppressed ischemic arrhythmias in a rat model of diabetes mellitus (DM)." | 7.78 | Berberine alleviates ischemic arrhythmias via recovering depressed I(to) and I(Ca) currents in diabetic rats. ( Fu, Y; Li, Q; Li, XL; Shan, HL; Sun, YQ; Wang, LH; Yu, HJ; Zhang, L, 2012) |
| " Recently, it has been demonstrated that berberine (BBR) exerts antiobesity and antidiabetic effects in obese and diabetic rodent models through the activation of AMPK in peripheral tissues." | 7.75 | Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. ( Cha, SH; Choe, SS; Jeong, HW; Kim, JB; Kim, WS; Lane, MD; Lee, KU; Lee, MR; Lee, YS; Oh, GT; Park, HS, 2009) |
| " A highly bioavailable berberine formulation termed Huang-Gui solid dispersion (HGSD), is a preparation of berberine coupled to sodium caprate and this markedly improving berberines bioavailability." | 5.56 | Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance ( Chen, L; Guan, F; Hatch, GM; Lv, X; Meng, Z; Yang, X; Yu, Y; Zhang, M; Zhang, Y, 2020) |
| "Berberine (BBR) is a material extracted from Chinese herbs, which has been used in the treatment of diabetes in Chinese medicine for thousands of years." | 5.46 | Protective effect of berberine on renal fibrosis caused by diabetic nephropathy. ( Li, Z; Zhang, W, 2017) |
| "Berberine chloride (BC) has been widely used as an unprescribed oral drug in China for the treatment of various diseases, and it is an active ingredient in many traditionally used medicinal plants." | 5.46 | Berberine chloride ameliorates oxidative stress, inflammation and apoptosis in the pancreas of Streptozotocin induced diabetic rats. ( Chandirasegaran, G; Elanchezhiyan, C; Ghosh, K; Sethupathy, S, 2017) |
| "Co-treatment with berberine inhibited such effects." | 5.40 | Uncoupling protein-2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS-1E cells and in diabetic mouse islets. ( Gao, Y; Huang, Y; Liu, J; Liu, L; Xu, G; Yu, X, 2014) |
| " Erectile dysfunction rats were screened out through the apomorphine test and randomly divided into the diabetes mellitus and berberine groups, and these animals were administered berberine (200 mg/kg/day) and normal saline by gavage for 4 weeks." | 4.12 | Berberine ameliorates erectile dysfunction in rats with streptozotocin-induced diabetes mellitus through the attenuation of apoptosis by inhibiting the SPHK1/S1P/S1PR2 and MAPK pathways. ( Chen, Y; Cui, K; Lan, R; Li, R; Ling, L; Liu, J; Liu, K; Luan, Y; Rao, K; Ruan, Y; Song, J; Sun, T; Wang, S; Wang, T; Yuan, P, 2022) |
| "Co-administration of metformin (250 mg/kg) with berberine (125 mg/kg) could not only further improve insulin sensitivity, but also demonstrate different alterations on gut microbial communities than that of their individual treatment in db/db mice." | 4.12 | Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice. ( Kong, APS; Li, D; Li, Z; Lyu, Y; Ming, X; Shaw, PC; Yuan, X; Zhang, C; Zhang, J; Zuo, Z, 2022) |
| "Berberine may slow the progression of prediabetes to T2DM in ZDF rats by improving GLP-2 secretion, intestinal permeability, and the structure of the gut microbiota." | 4.02 | Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. ( Jiang, Y; Kong, Y; Liu, H; Ren, H; Shan, C; Wang, J; Wang, S; Wang, Y; Yang, J; Yang, Y; Zheng, M, 2021) |
| "Dysregulated glucagon drives hyperfunction in hepatic glucose output, which is the main cause of persistent hyperglycemia in type 2 diabetes." | 3.96 | Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. ( Jiang, B; Jin, J; Liu, P; Sheng, L; Song, Y; Zhang, H; Zhong, Y; Zhou, H, 2020) |
| " Role of JAK2 in the Pathogenesis of Diabetic Erectile Dysfunction and an Intervention With Berberine." | 3.91 | Role of JAK2 in the Pathogenesis of Diabetic Erectile Dysfunction and an Intervention With Berberine. ( Jiang, H; Lan, R; Li, H; Liu, J; Song, J; Sun, T; Tang, Z; Wang, S; Wang, T; Ye, Z, 2019) |
| "The combination of resveratrol with glibenclamide may alleviate reperfusion-induced arrhythmias via an underlying mechanism not be only associated with the restoration of the protein expression of Kir6." | 3.91 | The protection of resveratrol and its combination with glibenclamide, but not berberine on the diabetic hearts against reperfusion-induced arrhythmias: the role of myocardial K ( Bozdogan, O; Eksioglu, D; Erim, F; Firat, T; Kaya, ST; Ozarslan, TO; Taskin, E; Yasar, S, 2019) |
| "Objective To explore the effect of berberine on cardiac fibrosis of diabetic rats by observing the expressions of serum transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF) , collagen type 1 (Col1) and collagen type 3 (Col3) in myocardial tissues of diabetic rats after berberine treatment." | 3.83 | [Berberine inhibits cardiac fibrosis of diabetic rats]. ( He, J; Liu, G; Lu, K; Shen, Y; Song, W, 2016) |
| "This study investigated the effects of berberine on amelioration of hyperglycemia and hyperlipidemia and the mechanism involved in high glucose and high fat diet-induced diabetic hamsters." | 3.81 | Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. ( Jin, J; Li, L; Li, P; Liu, C; Song, Y; Wang, Z; Wu, D; Xu, N; Zheng, X, 2015) |
| "The present study was designed to elucidate the potential mechanism underlying that berberine suppressed ischemic arrhythmias in a rat model of diabetes mellitus (DM)." | 3.78 | Berberine alleviates ischemic arrhythmias via recovering depressed I(to) and I(Ca) currents in diabetic rats. ( Fu, Y; Li, Q; Li, XL; Shan, HL; Sun, YQ; Wang, LH; Yu, HJ; Zhang, L, 2012) |
| " Recently, it has been demonstrated that berberine (BBR) exerts antiobesity and antidiabetic effects in obese and diabetic rodent models through the activation of AMPK in peripheral tissues." | 3.75 | Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. ( Cha, SH; Choe, SS; Jeong, HW; Kim, JB; Kim, WS; Lane, MD; Lee, KU; Lee, MR; Lee, YS; Oh, GT; Park, HS, 2009) |
| "Berberine (BBR) is a pentacyclic benzylisoquinoline alkaloid that can be found in diversity of medicinal plants." | 2.82 | Protective effects of berberine on various kidney diseases: Emphasis on the promising effects and the underlined molecular mechanisms. ( Abd-Alhameed, EK; Hassanein, EHM; Ibrahim, IM; Mohamed, NM; Ross, SA, 2022) |
| "Growing evidence has suggested that diabetic nephropathy is induced by multiple factors, such as dyslipidemia, hyperglycemia, hemodynamic abnormalities and oxidative stress, based on genetic susceptibility." | 2.52 | Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms. ( Ding, HH; Ni, WJ; Tang, LQ, 2015) |
| " However, the chemical profiles, metabolic transformation and pharmacokinetic behavior of XEC in vivo were unclear." | 1.91 | Metabolic profiling integrated with pharmacokinetics to reveal the material basis of Xiaokeyinshui extract combination in the treatment of type 2 diabetes in rats. ( Chen, JC; Fang, JB; Fu, XN; He, JX; Hu, ZF; Huang, R; Li, Q; Luo, D; Peng, HM; Tong, QL; Wan, LS; Wu, JL; Xia, RF; Xiang, ZN; Zhang, YL, 2023) |
| "Berberine is a compound for which both antidiabetic and antiosteoporotic effects have been documented." | 1.72 | Lack of berberine effect on bone mechanical properties in rats with experimentally induced diabetes. ( Cegieła, U; Folwarczna, J; Gajdoš, M; Janas, A; Kisiel-Nawrot, E; Kocik, S; Krivošíková, Z; Londzin, P; Skoczyńska, A; Štefíková, K, 2022) |
| "Berberine is an isoquinoline derivative alkaloid extracted from Chinese herbs." | 1.72 | Berberine Ameliorates Glucose Metabolism in Diabetic Rats through the alpha7 Nicotinic Acetylcholine Receptor-Related Cholinergic Anti-Inflammatory Pathway. ( Dong, H; Gong, J; Lu, F; Ren, Y; Sun, W; Wang, D; Wang, K; Xu, L; Zou, X, 2022) |
| " A pharmacokinetic analysis found a 6." | 1.72 | Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats. ( Abdelgawad, MA; Abou-Taleb, HA; Ali, MRA; Alsalahat, I; Eid, HM; Elkomy, MH; Elmowafy, M; Rateb, ME; Shalaby, K; Zafar, A, 2022) |
| "Berberine is effective for type 2 diabetes mellitus (T2DM), but has limited use in clinic." | 1.62 | Berberine combined with stachyose improves glycometabolism and gut microbiota through regulating colonic microRNA and gene expression in diabetic rats. ( Cao, H; Fu, Y; Gao, X; Huan, Y; Ji, W; Lei, L; Li, C; Li, P; Liu, M; Liu, Q; Liu, S; Shen, Z; Sun, S, 2021) |
| "Postprandial hyperglycemia is an important causative factor of type 2 diabetes mellitus, and permanent localization of intestinal GLUT2 in the brush border membrane is an important reason of postprandial hyperglycemia." | 1.62 | Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice. ( Dong, L; Li, J; Yang, E; Yang, H; Zhang, M, 2021) |
| "Berberine (BBR) has therapeutic effect on diabetic nephropathy (DN), but its molecular mechanism is not completely clear." | 1.62 | Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells. ( Gan, L; Hu, Y; Liu, L; Xiang, P; Xing, Y; Xu, J; Ye, S; Zhu, J, 2021) |
| "Berberine is an isoquinoline alkaloid, found in several plants." | 1.62 | Berberine modulates crucial erectogenic biomolecules and alters histological architecture in penile tissues of diabetic rats. ( Adefegha, SA; Dada, FA; Oboh, G; Okeke, BM; Oyeleye, SI, 2021) |
| "Berberine (BBR) is a promising anti-diabetic isoquinoline alkaloid from Rhizoma coptidis, while its bioavailability was extremely low." | 1.62 | Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways. ( Ai, G; Chen, H; Chen, J; Dou, Y; Huang, R; Li, Q; Li, Y; Liu, Y; Luo, C; Su, Z; Xie, J; Zeng, H, 2021) |
| "Berberine has been shown to promising effect for IR in vitro and in vivo." | 1.62 | Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway. ( Bao, Y; Chen, Q; Han, Y; Liu, C; Liu, W; Liu, X; Wang, J; Wu, N; Ye, Y; Yu, Y, 2021) |
| "Rat models of type 2 diabetes mellitus (T2DM) were established and were treated with berberine." | 1.62 | Macrovascular Protecting Effects of Berberine through Anti-inflammation and Intervention of BKCa in Type 2 Diabetes Mellitus Rats. ( Chen, M; Gu, L; Si, Y; Wu, Z; Yin, W; Zhang, T; Zhao, M, 2021) |
| " A highly bioavailable berberine formulation termed Huang-Gui solid dispersion (HGSD), is a preparation of berberine coupled to sodium caprate and this markedly improving berberines bioavailability." | 1.56 | Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance ( Chen, L; Guan, F; Hatch, GM; Lv, X; Meng, Z; Yang, X; Yu, Y; Zhang, M; Zhang, Y, 2020) |
| " However, the poor bioavailability of berberine limits its clinical applications." | 1.56 | Highly bioavailable berberine formulation ameliorates diabetic nephropathy through the inhibition of glomerular mesangial matrix expansion and the activation of autophagy. ( Chen, L; Guan, F; Wang, X; Xiao, D; Zhang, J; Zhang, M; Zhang, Y, 2020) |
| " This study aimed to evaluate whether BBR combined with Sta produced better glycometabolism than BBR alone, and explored the effects on gut microbiota and metabolomics." | 1.56 | Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice. ( Bai, GL; Cao, H; Han, YW; Huan, Y; Lei, L; Li, CN; Li, RC; Liu, MZ; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ; Wang, X; Zhou, T, 2020) |
| " However, its oral bioavailability is poor." | 1.56 | Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids. ( Chen, H; Wang, D; Wang, W; Yan, L; Yao, Y, 2020) |
| "Berberine (BBR) is an important natural product with poor gastrointestinal behavior includes low permeability, P-glycoprotein efflux, and mass elimination in the intestine." | 1.51 | Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge. ( Chen, L; Huang, CL; Huang, SH; Liu, CS; Long, XY; Xu, HY; Zheng, YR, 2019) |
| "Berberine (BBR) has been well characterized to exert renoprotective effects in DN progression." | 1.48 | Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. ( Han, J; Pang, W; Xue, L; Yuan, R; Zhu, L, 2018) |
| "Berberine (BBR) has been reported to ameliorate diabetes and diabetic encephalopathy (DE)." | 1.48 | Berberine Improves Diabetic Encephalopathy Through the SIRT1/ER Stress Pathway in db/db Mice. ( Chen, YB; Cheng, SY; Fang, JS; Hao, XY; Li, HY; Luo, NC; Luo, S; Wang, Q; Wang, XC; Xu, YM; Zhang, SJ, 2018) |
| "Berberine has many pharmacological effects, such as antidiabetic, antimicrobial, anti-inflammatory, and antioxidant, but the question remains on how its low oral bioavailability has greatly limited its clinical application." | 1.48 | Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability. ( Cui, HX; Guo, Y; Hu, YN; Li, JW; Yuan, K, 2018) |
| "Berberine is an active alkaloid isolated from Rhizoma coptidis [Coptis chinensis Franch." | 1.46 | Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. ( Jia, Y; Xu, B; Xu, J, 2017) |
| "Berberine (BBR) is a material extracted from Chinese herbs, which has been used in the treatment of diabetes in Chinese medicine for thousands of years." | 1.46 | Protective effect of berberine on renal fibrosis caused by diabetic nephropathy. ( Li, Z; Zhang, W, 2017) |
| " The preclinical acute dose toxicity study and 90-days repeated dose toxicity study of DB14201 extract in wistar rats by oral route indicated that the extract is safe up to 1000mg/kg dose." | 1.46 | Antidiabetic potential of polyherbal formulation DB14201: Preclinical development, safety and efficacy studies. ( Awasthi, A; Bharate, SS; Gopalakrishna Pillai, GK; Jaggi, M; Mishra, G; Mithal, A; Singh, AT; Verma, R; Vishwakarma, RA, 2017) |
| "Treatment of pioglitazone and berberine alone and in combination significantly ameliorate abnormal blood glucose, serum insulin, and HbA1c levels in streptozotocin-induced diabetic rats." | 1.46 | Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk. ( Adil, M; Kandhare, AD; Mansoori, MN; Sharma, M; Singh, D, 2017) |
| "Berberine chloride (BC) has been widely used as an unprescribed oral drug in China for the treatment of various diseases, and it is an active ingredient in many traditionally used medicinal plants." | 1.46 | Berberine chloride ameliorates oxidative stress, inflammation and apoptosis in the pancreas of Streptozotocin induced diabetic rats. ( Chandirasegaran, G; Elanchezhiyan, C; Ghosh, K; Sethupathy, S, 2017) |
| "Berberine (BBR) has been shown to have antifibrotic effects in liver, kidney and lung." | 1.43 | Protective Effects of Berberine on Renal Injury in Streptozotocin (STZ)-Induced Diabetic Mice. ( Chi, ZH; He, H; Jiang, Y; Liang, D; Liang, W; Ma, J; Zhang, X, 2016) |
| "Berberine has been shown to exert protective effects against diabetic nephropathy (DN), but the mechanisms involved have not been fully characterized." | 1.43 | Renoprotective effects of berberine and its potential effect on the expression of β-arrestins and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in streptozocin-diabetic nephropathy rats. ( Cai, M; Ding, HH; Liu, S; Ni, WJ; Tang, LQ; Zhang, ST, 2016) |
| "Berberine has proven protective effects on diabetic nephropathy, but the mechanism for its effects has not been comprehensively established." | 1.42 | Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats. ( Ding, HH; Ni, WJ; Qiu, YY; Tang, LQ; Zhou, H, 2015) |
| "Berberine is known to improve glucose and lipid metabolism disorders, but it poorly absorbed into the blood stream from the gut." | 1.40 | Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine. ( Li, M; Li, W; Ping, F; Wang, Z; Xiao, X; Yu, M; Zhang, H; Zhang, Q; Zheng, J, 2014) |
| "Berberine (BBR) has several preventive effects on diabetes and its complications." | 1.40 | Berberine improves kidney function in diabetic mice via AMPK activation. ( Guan, GJ; Nie, HB; Sun, LN; Wang, XL; Zhao, L, 2014) |
| "Berberine (BBR) has preventive effects on diabetes and its complications." | 1.40 | Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy. ( Liu, S; Tang, LQ; Wang, FL; Zhang, ST; Zhu, LN, 2014) |
| "Co-treatment with berberine inhibited such effects." | 1.40 | Uncoupling protein-2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS-1E cells and in diabetic mouse islets. ( Gao, Y; Huang, Y; Liu, J; Liu, L; Xu, G; Yu, X, 2014) |
| " The concentrations of berberine in non-diabetic mice plasma were determined using HPLC, and main pharmacokinetic parameters were investigated." | 1.39 | The anti-diabetic effects and pharmacokinetic profiles of berberine in mice treated with Jiao-Tai-Wan and its compatibility. ( Chen, G; Dong, H; Huang, Z; Lu, F; Wang, F; Xu, L; Yi, P; Zou, X, 2013) |
| "Berberine (BBR) treatment significantly inhibited renal inflammation and thus improved renal damage in diabetes." | 1.39 | Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of RhoA/ROCK signaling. ( Chang, X; Chen, L; Huang, H; Huang, J; Huang, K; Liu, P; Shen, X; Wang, S; Xie, X, 2013) |
| "Berberine treatment for 8 weeks abolished the above changes by upregulating the expression of Gαs protein and downregulating the expression of Gαi protein, increasing cAMP level, and inhibiting MCs proliferation compared with model group." | 1.39 | Berberine ameliorates renal injury by regulating G proteins-AC- cAMP signaling in diabetic rats with nephropathy. ( Liu, S; Lv, F; Tang, LQ; Wang, FL; Zhang, ST; Zhu, LN, 2013) |
| " However, the poor bioavailability of this agent greatly limits its clinical application." | 1.38 | Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis. ( Chang, W; Chen, L; Li, J; Li, W; Liu, Y; Lv, X; Meng, Z; Wang, Q; Zhang, M, 2012) |
| "Berberine (BBR) treatment also effectively inhibits SphK1 activity and S1P production in the kidneys of diabetic models, thus improving renal injury." | 1.38 | Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models. ( Huang, H; Huang, J; Huang, K; Lan, T; Liu, P; Liu, W; Peng, J; Shen, X; Wang, S; Xie, X, 2012) |
| "Berberine (BBR) is a compound originally identified in a Chinese herbal medicine Huanglian (Coptis chinensis French)." | 1.37 | Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. ( Liang, H; Shen, Y; Tang, K; Weng, J; Xia, X; Yan, J; Yang, D; Ye, J; Yin, J; Zhang, Y, 2011) |
| "To enhance oral bioavailability and anti-diabetic efficacy of berberine (BER), an anhydrous reverse micelle (ARM) delivery system was prepared through lyophilization of water-in-oil (W/O) emulsions." | 1.37 | Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. ( Hao, A; Li, T; Song, H; Wang, J; Wang, N; Wang, T; Xi, X, 2011) |
| "The rat model of diabetic nephropathy was induced by injection of streptozocin (STZ)." | 1.37 | [Effect of berberine on expression of transforming growth factor-beta1 and type IV collagen proteins in mesangial cells of diabetic rats with nephropathy]. ( Liu, S; Lv, F; Tang, L; Zhang, S, 2011) |
| "One of the main pathological changes in diabetic nephropathy is the renal fibrosis, which includes glomerulosclerosis and tubulointerstitial fibrosis." | 1.36 | Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. ( Huang, H; Jiang, Q; Lan, T; Li, W; Liu, P; Liu, W; Shen, X; Xie, X; Zhang, X, 2010) |
| "Berberine (BBR) was previously found to have beneficial effects on renal injury in experimental diabetic rats." | 1.36 | Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway. ( Huang, H; Jiang, Q; Lan, T; Li, W; Liu, P; Liu, W; Shen, X; Xie, X; Xu, S, 2010) |
| " However, the facts that berberine had low bioavailability and poor absorption through the gut wall indicated that berberine might exert its antihyperglycaemic effect in the intestinal tract before absorption." | 1.35 | Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats. ( Deng, Y; Liu, L; Liu, X; Lu, S; Xie, L; Yu, S, 2008) |
| "Berberine treatment significantly increased serum SOD activity and decreased the content of MDA compared with diabetic model group (P < 0." | 1.35 | Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. ( Chen, FY; Chen, SR; Deng, YH; Guo, FF; Hei, ZQ; Huang, HQ; Huang, WG; Li, XJ; Liu, PQ; Liu, WH; Nie, H; Tang, FT, 2008) |
| " In conclusion, berberine restores diabetic endothelial dysfunction through enhanced NO bioavailability by up-regulating eNOS expression and down-regulating expression of NADPH oxidase." | 1.35 | Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. ( Chen, L; Li, J; Liu, Y; Lv, X; Song, Y; Wang, C; Zhang, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (8.27) | 29.6817 |
| 2010's | 73 (54.89) | 24.3611 |
| 2020's | 47 (35.34) | 2.80 |
| Authors | Studies |
|---|---|
| Li, C | 2 |
| Cao, H | 2 |
| Huan, Y | 2 |
| Ji, W | 1 |
| Liu, S | 8 |
| Sun, S | 2 |
| Liu, Q | 2 |
| Lei, L | 2 |
| Liu, M | 2 |
| Gao, X | 4 |
| Fu, Y | 3 |
| Li, P | 3 |
| Shen, Z | 1 |
| Xu, J | 4 |
| Liu, L | 5 |
| Gan, L | 1 |
| Hu, Y | 1 |
| Xiang, P | 1 |
| Xing, Y | 1 |
| Zhu, J | 1 |
| Ye, S | 1 |
| Liu, K | 1 |
| Sun, T | 2 |
| Luan, Y | 1 |
| Chen, Y | 2 |
| Song, J | 5 |
| Ling, L | 1 |
| Yuan, P | 1 |
| Li, R | 1 |
| Cui, K | 1 |
| Ruan, Y | 2 |
| Lan, R | 2 |
| Wang, T | 5 |
| Wang, S | 7 |
| Liu, J | 5 |
| Rao, K | 1 |
| Zhang, M | 9 |
| Yang, H | 3 |
| Yang, E | 1 |
| Li, J | 5 |
| Dong, L | 3 |
| Londzin, P | 1 |
| Kocik, S | 1 |
| Kisiel-Nawrot, E | 1 |
| Janas, A | 1 |
| Skoczyńska, A | 1 |
| Krivošíková, Z | 1 |
| Štefíková, K | 1 |
| Gajdoš, M | 1 |
| Cegieła, U | 1 |
| Folwarczna, J | 2 |
| Zhang, JJ | 1 |
| Zhou, R | 2 |
| Deng, LJ | 1 |
| Cao, GZ | 1 |
| Zhang, Y | 8 |
| Xu, H | 2 |
| Hou, JY | 1 |
| Ju, S | 1 |
| Yang, HJ | 1 |
| Lyu, Y | 1 |
| Li, D | 2 |
| Yuan, X | 1 |
| Li, Z | 3 |
| Zhang, J | 4 |
| Ming, X | 1 |
| Shaw, PC | 1 |
| Zhang, C | 3 |
| Kong, APS | 1 |
| Zuo, Z | 2 |
| Ma, Z | 2 |
| Zhu, L | 2 |
| Guo, X | 1 |
| Sun, B | 1 |
| Wang, Q | 5 |
| Chen, L | 11 |
| Hassanein, EHM | 1 |
| Ibrahim, IM | 1 |
| Abd-Alhameed, EK | 1 |
| Mohamed, NM | 1 |
| Ross, SA | 1 |
| Bi, XJ | 1 |
| Lv, YQ | 1 |
| Yang, XH | 1 |
| Ge, Y | 1 |
| Han, H | 1 |
| Feng, JS | 1 |
| Xu, MZ | 1 |
| Guan, FY | 1 |
| Elkomy, MH | 1 |
| Eid, HM | 1 |
| Elmowafy, M | 1 |
| Shalaby, K | 1 |
| Zafar, A | 1 |
| Abdelgawad, MA | 1 |
| Rateb, ME | 1 |
| Ali, MRA | 1 |
| Alsalahat, I | 1 |
| Abou-Taleb, HA | 1 |
| Lu, M | 1 |
| Wang, Y | 5 |
| Jiang, Y | 3 |
| Wang, H | 2 |
| Sha, W | 1 |
| Lei, T | 1 |
| Tong, QL | 1 |
| Luo, D | 1 |
| Xiang, ZN | 1 |
| Zhang, YL | 1 |
| He, JX | 1 |
| Hu, ZF | 1 |
| Xia, RF | 1 |
| Wu, JL | 1 |
| Fu, XN | 1 |
| Li, Q | 4 |
| Peng, HM | 1 |
| Huang, R | 2 |
| Wan, LS | 1 |
| Chen, JC | 1 |
| Fang, JB | 1 |
| Wang, L | 1 |
| Wang, J | 4 |
| Ren, G | 1 |
| Nishikawa, K | 1 |
| Yu, J | 2 |
| Dodangeh, A | 1 |
| Hoveizi, E | 1 |
| Tabatabaei, SRF | 1 |
| Zhao, S | 1 |
| Sun, L | 2 |
| Yin, Z | 2 |
| Wang, X | 4 |
| Li, X | 4 |
| Iwakiri, Y | 1 |
| Han, J | 2 |
| Duan, Y | 1 |
| Zhao, L | 3 |
| Wang, M | 1 |
| Zhi, M | 1 |
| Geng, X | 1 |
| Hou, C | 1 |
| Wang, W | 2 |
| Zhao, D | 2 |
| Zhai, J | 1 |
| Zhang, H | 6 |
| Ma, L | 2 |
| Zou, J | 1 |
| Li, M | 2 |
| Zhang, W | 2 |
| Xu, JH | 1 |
| Yu, T | 1 |
| Chen, QK | 1 |
| Tang, Z | 2 |
| Li, H | 2 |
| Jiang, H | 2 |
| Ye, Z | 1 |
| Zhang, P | 2 |
| He, L | 1 |
| Mei, X | 1 |
| Tian, H | 1 |
| Chen, Z | 2 |
| Li, CN | 1 |
| Liu, MZ | 1 |
| Li, RC | 1 |
| Sun, SJ | 1 |
| Liu, SN | 1 |
| Zhou, T | 1 |
| Bai, GL | 1 |
| Han, YW | 1 |
| Shen, ZF | 1 |
| Zhong, Y | 1 |
| Jin, J | 2 |
| Liu, P | 9 |
| Song, Y | 3 |
| Sheng, L | 1 |
| Zhou, H | 3 |
| Jiang, B | 1 |
| Xiao, D | 1 |
| Guan, F | 3 |
| Liu, Z | 1 |
| Yao, Y | 3 |
| Zuo, J | 1 |
| Wei, Y | 1 |
| Liu, X | 4 |
| Wang, K | 3 |
| Zhou, J | 3 |
| Sullivan, MA | 1 |
| Liu, Y | 6 |
| Gilbert, RG | 1 |
| Deng, B | 1 |
| Zych, M | 1 |
| Wojnar, W | 1 |
| Kielanowska, M | 1 |
| Kaczmarczyk-Sedlak, I | 1 |
| Xu, XH | 1 |
| Hu, Q | 1 |
| Zhou, LS | 1 |
| Xu, LJ | 3 |
| Zou, X | 4 |
| Lu, FE | 3 |
| Yi, P | 3 |
| Pan, J | 1 |
| Xiang, Z | 1 |
| Tong, Q | 1 |
| Fang, J | 1 |
| Wan, L | 1 |
| Chen, J | 3 |
| Bozcaarmutlu, A | 1 |
| Sapmaz, C | 1 |
| Bozdoğan, Ö | 2 |
| Kükner, A | 1 |
| Kılınç, L | 1 |
| Kaya, ST | 2 |
| Özarslan, OT | 1 |
| Ekşioğlu, D | 2 |
| Meng, Z | 2 |
| Yu, Y | 3 |
| Yang, X | 1 |
| Lv, X | 3 |
| Hatch, GM | 2 |
| Wu, Z | 1 |
| Gu, L | 1 |
| Si, Y | 1 |
| Yin, W | 1 |
| Zhao, M | 2 |
| Zhang, T | 1 |
| Chen, M | 1 |
| Chen, H | 3 |
| Yan, L | 1 |
| Wang, D | 2 |
| Shao, J | 1 |
| Zheng, X | 2 |
| Li, L | 3 |
| Zhu, Z | 1 |
| Xiang, C | 1 |
| Cao, G | 1 |
| Dou, Y | 1 |
| Li, Y | 3 |
| Ai, G | 1 |
| Xie, J | 1 |
| Zeng, H | 1 |
| Luo, C | 1 |
| Su, Z | 1 |
| Xiao, Y | 1 |
| Deng, J | 1 |
| Gong, X | 1 |
| Gui, Z | 1 |
| Huang, J | 4 |
| Ye, X | 1 |
| Ren, Y | 1 |
| Sun, W | 1 |
| Gong, J | 1 |
| Dong, H | 3 |
| Xu, L | 2 |
| Lu, F | 2 |
| Fan, CF | 1 |
| Guo, YS | 1 |
| Wang, JH | 1 |
| Zhang, HL | 1 |
| Adefegha, SA | 2 |
| Dada, FA | 2 |
| Oyeleye, SI | 2 |
| Oboh, G | 2 |
| Wu, N | 1 |
| Liu, W | 7 |
| Han, Y | 1 |
| Ye, Y | 1 |
| Chen, Q | 1 |
| Bao, Y | 1 |
| Liu, C | 2 |
| Tan, R | 1 |
| Yuan, T | 1 |
| Chen, S | 1 |
| Quan, Y | 1 |
| Hao, Q | 1 |
| Zeng, J | 1 |
| Zhao, J | 1 |
| Okeke, BM | 1 |
| Di, S | 1 |
| Han, L | 1 |
| An, X | 1 |
| Kong, R | 1 |
| Gao, Z | 1 |
| Yang, Y | 3 |
| Ding, Q | 1 |
| Wu, H | 2 |
| Tong, X | 1 |
| Guo, H | 1 |
| Guo, Q | 1 |
| Lan, T | 6 |
| Luo, Y | 1 |
| Pan, X | 1 |
| Feng, Y | 1 |
| Tao, L | 1 |
| Shen, X | 6 |
| Liu, H | 2 |
| Zheng, M | 1 |
| Ren, H | 1 |
| Kong, Y | 1 |
| Yang, J | 1 |
| Shan, C | 1 |
| Zhang, JH | 2 |
| Yang, HZ | 1 |
| Su, H | 2 |
| Bai, Y | 2 |
| Deng, L | 2 |
| Feng, CP | 2 |
| Guo, HX | 2 |
| Gu, Y | 2 |
| Zhen, Z | 2 |
| Lu, Y | 1 |
| Feng, X | 1 |
| Cao, S | 1 |
| Ding, L | 1 |
| Qiu, F | 1 |
| Zhang, JF | 1 |
| Xu, XY | 1 |
| Jin, C | 1 |
| Zheng, JF | 1 |
| Yang, G | 1 |
| Zhao, Z | 1 |
| Zhang, X | 6 |
| Wu, A | 1 |
| Huang, Y | 3 |
| Miao, Y | 1 |
| Yang, M | 3 |
| Chen, DL | 1 |
| Yang, KY | 1 |
| Li, HY | 1 |
| Wang, XC | 1 |
| Xu, YM | 1 |
| Luo, NC | 1 |
| Luo, S | 1 |
| Hao, XY | 1 |
| Cheng, SY | 1 |
| Fang, JS | 1 |
| Zhang, SJ | 1 |
| Chen, YB | 1 |
| M S, S | 1 |
| C D, N | 1 |
| Adil, M | 1 |
| Mansoori, MN | 1 |
| Singh, D | 1 |
| Kandhare, AD | 1 |
| Sharma, M | 1 |
| Chandirasegaran, G | 2 |
| Elanchezhiyan, C | 2 |
| Ghosh, K | 2 |
| Sethupathy, S | 1 |
| Zan, Y | 1 |
| Kuai, CX | 1 |
| Qiu, ZX | 1 |
| Huang, F | 1 |
| Yerra, VG | 1 |
| Kalvala, AK | 1 |
| Sherkhane, B | 1 |
| Areti, A | 1 |
| Kumar, A | 2 |
| Ozarslan, TO | 1 |
| Taskin, E | 1 |
| Erim, F | 1 |
| Firat, T | 1 |
| Yasar, S | 1 |
| Yuan, R | 1 |
| Xue, L | 1 |
| Pang, W | 1 |
| Sun, J | 1 |
| Bao, H | 1 |
| Peng, Y | 1 |
| Sun, Y | 1 |
| Qi, J | 1 |
| Gao, Y | 2 |
| Li, G | 2 |
| Xing, W | 1 |
| Geng, F | 2 |
| Gao, F | 2 |
| Xie, H | 1 |
| Hu, W | 1 |
| Manicum, T | 1 |
| Wu, Y | 1 |
| Huang, X | 1 |
| Yu, Z | 1 |
| Cui, HX | 2 |
| Hu, YN | 2 |
| Li, JW | 2 |
| Yuan, K | 2 |
| Guo, Y | 1 |
| Dong, J | 1 |
| Yan, W | 1 |
| Zheng, Q | 1 |
| Zong, GN | 1 |
| Zhang, KQ | 1 |
| Shi, LL | 1 |
| Jia, WH | 1 |
| Zhang, L | 4 |
| Xu, CY | 1 |
| Chen, X | 1 |
| Yin, L | 1 |
| Wang, NQ | 1 |
| Fang, LH | 1 |
| Qiang, GF | 1 |
| Yang, XY | 1 |
| Du, GH | 1 |
| Xu, HY | 1 |
| Liu, CS | 1 |
| Huang, CL | 1 |
| Zheng, YR | 1 |
| Huang, SH | 1 |
| Long, XY | 1 |
| Chen, G | 1 |
| Wang, F | 1 |
| Huang, Z | 1 |
| Moghaddam, HK | 2 |
| Baluchnejadmojarad, T | 3 |
| Roghani, M | 3 |
| Goshadrou, F | 2 |
| Ronaghi, A | 2 |
| Xie, X | 5 |
| Chang, X | 1 |
| Huang, K | 3 |
| Huang, H | 6 |
| Khaksari, M | 1 |
| Norouzi, P | 1 |
| Ahooie, M | 1 |
| Mahboobi, F | 1 |
| Tian, P | 1 |
| Ge, H | 1 |
| Kern, TS | 1 |
| Du, L | 2 |
| Guan, L | 1 |
| Su, S | 1 |
| Ren, LM | 1 |
| Zhuo, YJ | 1 |
| Hao, ZS | 1 |
| He, HM | 1 |
| Lu, HG | 1 |
| Tang, LQ | 8 |
| Zhang, ST | 3 |
| Zhu, LN | 3 |
| Wang, FL | 3 |
| Yu, X | 1 |
| Xu, G | 1 |
| Chen, K | 1 |
| Zhang, Z | 1 |
| Ni, W | 1 |
| Cai, M | 3 |
| Tang, L | 2 |
| Wei, W | 3 |
| Zhang, Q | 1 |
| Xiao, X | 1 |
| Li, W | 5 |
| Yu, M | 1 |
| Ping, F | 1 |
| Wang, Z | 2 |
| Zheng, J | 1 |
| Jiang, S | 1 |
| Qian, DW | 1 |
| Shang, EX | 1 |
| Su, SL | 1 |
| Leng, XJ | 1 |
| Guo, JM | 1 |
| Duan, JA | 1 |
| Sun, LN | 1 |
| Nie, HB | 1 |
| Wang, XL | 1 |
| Guan, GJ | 1 |
| Wu, D | 2 |
| Xu, N | 1 |
| Ni, WJ | 4 |
| Ding, HH | 4 |
| Jiang, SJ | 1 |
| Li, JB | 1 |
| Wang, KF | 1 |
| Qiu, YY | 2 |
| Chang, W | 2 |
| Li, K | 1 |
| Yao, F | 1 |
| Ma, YG | 1 |
| Zhang, YB | 1 |
| Bai, YG | 1 |
| Dai, ZJ | 1 |
| Liang, L | 1 |
| Xie, MJ | 1 |
| Guan, HT | 1 |
| Gopalakrishna Pillai, GK | 1 |
| Bharate, SS | 1 |
| Awasthi, A | 1 |
| Verma, R | 1 |
| Mishra, G | 1 |
| Singh, AT | 1 |
| Jaggi, M | 1 |
| Mithal, A | 1 |
| Vishwakarma, RA | 1 |
| Tian, CM | 1 |
| Jiang, X | 1 |
| Ouyang, XX | 1 |
| Zhang, YO | 1 |
| Xie, WD | 1 |
| He, H | 1 |
| Liang, D | 1 |
| Liang, W | 1 |
| Chi, ZH | 1 |
| Ma, J | 1 |
| Lu, K | 1 |
| Shen, Y | 2 |
| He, J | 1 |
| Liu, G | 1 |
| Song, W | 1 |
| Wu, YS | 1 |
| Chen, YT | 1 |
| Bao, YT | 1 |
| Li, ZM | 1 |
| Zhou, XJ | 1 |
| He, JN | 1 |
| Dai, SJ | 1 |
| Li, CY | 1 |
| Jia, Y | 1 |
| Xu, B | 1 |
| Zhou, JY | 3 |
| Zhou, SW | 3 |
| Zhang, KB | 1 |
| Tang, JL | 1 |
| Guang, LX | 1 |
| Ying, Y | 2 |
| Xu, Y | 2 |
| Li, DD | 1 |
| Deng, Y | 2 |
| Yu, S | 1 |
| Lu, S | 1 |
| Xie, L | 2 |
| Liu, WH | 1 |
| Hei, ZQ | 1 |
| Nie, H | 1 |
| Tang, FT | 1 |
| Huang, HQ | 1 |
| Li, XJ | 1 |
| Deng, YH | 1 |
| Chen, SR | 1 |
| Guo, FF | 1 |
| Huang, WG | 1 |
| Chen, FY | 1 |
| Liu, PQ | 1 |
| Kim, WS | 1 |
| Lee, YS | 1 |
| Cha, SH | 1 |
| Jeong, HW | 1 |
| Choe, SS | 1 |
| Lee, MR | 1 |
| Oh, GT | 1 |
| Park, HS | 1 |
| Lee, KU | 1 |
| Lane, MD | 1 |
| Kim, JB | 1 |
| Zhou, S | 1 |
| Tang, J | 1 |
| Zhang, K | 1 |
| Guang, L | 1 |
| Wang, C | 1 |
| Yu, YL | 1 |
| Yang, JS | 1 |
| Liu, YW | 1 |
| Liang, Y | 1 |
| Liu, XD | 1 |
| Wang, GJ | 1 |
| Campbell, T | 1 |
| Perry, B | 1 |
| Beaurepaire, C | 1 |
| Qin, L | 1 |
| Jiang, Q | 2 |
| Xu, S | 1 |
| Bhutada, P | 1 |
| Mundhada, Y | 1 |
| Bansod, K | 1 |
| Tawari, S | 1 |
| Patil, S | 1 |
| Dixit, P | 1 |
| Umathe, S | 1 |
| Mundhada, D | 1 |
| Xia, X | 1 |
| Yan, J | 1 |
| Tang, K | 1 |
| Yin, J | 1 |
| Yang, D | 1 |
| Liang, H | 1 |
| Ye, J | 1 |
| Weng, J | 1 |
| Meskheli, MB | 2 |
| Antelava, NA | 2 |
| Bakuridze, AD | 2 |
| Berishvili, ER | 1 |
| Pachkoriia, KZ | 1 |
| Gongadze, MV | 1 |
| Okudzhava, MV | 1 |
| Peng, J | 2 |
| Wang, N | 1 |
| Song, H | 1 |
| Xi, X | 1 |
| Hao, A | 1 |
| Li, T | 1 |
| Wang, LH | 1 |
| Li, XL | 1 |
| Yu, HJ | 1 |
| Sun, YQ | 1 |
| Shan, HL | 1 |
| Lv, F | 2 |
| Zhang, S | 1 |
| Wen, W | 1 |
| Qi, CL | 1 |
| Zhao, RX | 1 |
| Lü, JH | 1 |
| Zhong, CY | 1 |
| Chen, YY | 1 |
| Deng, YX | 1 |
| Zhang, XJ | 1 |
| Shi, QZ | 1 |
| Chen, YS | 1 |
| Qiu, XM | 1 |
| Chen, B | 1 |
| Bharti, SK | 1 |
| Krishnan, S | 1 |
| Rajak, KK | 1 |
| Murari, K | 1 |
| Bharti, BK | 1 |
| Gupta, AK | 1 |
| Kalalian-Moghaddam, H | 1 |
| Yang, F | 1 |
| Leng, SH | 1 |
| Hu, B | 1 |
| Tang, Q | 1 |
| Fu, Q | 1 |
| Xiang, J | 1 |
| Chen, LM | 1 |
| Tao, S | 1 |
| Guo, F | 1 |
| Huang, W | 1 |
| Chen, F | 1 |
| Zhou, SF | 1 |
| Ni, YX | 1 |
| Chen, QM | 1 |
| Xie, MZ | 1 |
2 reviews available for berberine and Alloxan Diabetes
| Article | Year |
|---|---|
Protective effects of berberine on various kidney diseases: Emphasis on the promising effects and the underlined molecular mechanisms.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney | 2022 |
Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Humans; | 2015 |
1 trial available for berberine and Alloxan Diabetes
| Article | Year |
|---|---|
Leukocytes from diabetic patients kill retinal endothelial cells: effects of berberine.
Topics: Animals; Apoptosis; Berberine; CD18 Antigens; Cell Adhesion; Diabetes Mellitus, Experimental; Endoth | 2013 |
130 other studies available for berberine and Alloxan Diabetes
| Article | Year |
|---|---|
Berberine combined with stachyose improves glycometabolism and gut microbiota through regulating colonic microRNA and gene expression in diabetic rats.
Topics: Animals; Berberine; Colon; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gastrointesti | 2021 |
Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells.
Topics: Animals; Apoptosis; Berberine; CCAAT-Enhancer-Binding Protein-beta; Diabetes Mellitus, Experimental; | 2021 |
Berberine ameliorates erectile dysfunction in rats with streptozotocin-induced diabetes mellitus through the attenuation of apoptosis by inhibiting the SPHK1/S1P/S1PR2 and MAPK pathways.
Topics: Animals; Apoptosis; Berberine; Diabetes Mellitus, Experimental; Erectile Dysfunction; Lysophospholip | 2022 |
Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cell Line; Diabetes Mellitus, Experimental; Epitheli | 2021 |
Lack of berberine effect on bone mechanical properties in rats with experimentally induced diabetes.
Topics: Animals; Berberine; Bone Density; Bone Remodeling; Diabetes Mellitus, Experimental; Diabetes Mellitu | 2022 |
Huangbai liniment and berberine promoted wound healing in high-fat diet/Streptozotocin-induced diabetic rats.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug | 2022 |
Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice.
Topics: Animals; Berberine; Chromatography, Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2022 |
Berberine protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition involving the inactivation of the NLRP3 inflammasome.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Glucose; Infl | 2022 |
A New Berberine Preparation Protects Pancreatic Islet Cells from Apoptosis Mediated by Inhibition of Phospholipase A
Topics: Animals; Apoptosis; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin-S | 2022 |
Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats.
Topics: Administration, Oral; Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Dietary Su | 2022 |
Berberine inhibits gluconeogenesis in spontaneous diabetic rats by regulating the AKT/MAPK/NO/cGMP/PKG signaling pathway.
Topics: Animals; Berberine; Cyclic GMP; Diabetes Mellitus, Experimental; Gluconeogenesis; Proto-Oncogene Pro | 2023 |
Metabolic profiling integrated with pharmacokinetics to reveal the material basis of Xiaokeyinshui extract combination in the treatment of type 2 diabetes in rats.
Topics: Alkaloids; Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drugs, Ch | 2023 |
Ameliorative effects of the Coptis inflorescence extract against lung injury in diabetic mice by regulating AMPK/NEU1 signaling.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Coptis; Diabetes Mellitus, Experimental; Inflores | 2023 |
Simultaneous Administration of Berberine and Transplantation of Endometrial Stem Cell-Derived Insulin Precursor Cells on a Nanofibrous Scaffold to Treat Diabetes Mellitus in Mice.
Topics: Animals; Berberine; Blood Glucose; Cell Differentiation; Diabetes Mellitus, Experimental; Humans; In | 2023 |
Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Homeostasis | 2023 |
Berberine restored nitrergic and adrenergic function in mesenteric and iliac arteries from streptozotocin-induced diabetic rats.
Topics: Adrenergic Neurons; Animals; Berberine; Diabetes Mellitus, Experimental; Iliac Artery; Male; Mesente | 2019 |
Coptisine ameliorates renal injury in diabetic rats through the activation of Nrf2 signaling pathway.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Heme Oxygenase (Decycli | 2020 |
Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2019 |
Role of JAK2 in the Pathogenesis of Diabetic Erectile Dysfunction and an Intervention With Berberine.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Erectile Dysfunction; Janus Kinase 2; Male; Myo | 2019 |
Preparation of novel berberine nano-colloids for improving wound healing of diabetic rats by acting Sirt1/NF-κB pathway.
Topics: Animals; Berberine; Cell Line; Cell Movement; Cell Proliferation; Colloids; Diabetes Mellitus, Exper | 2020 |
Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Feces; Gastrointestinal Microbiome; Male; Metab | 2020 |
Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Glucagon; Hyperglycemia; Liver; Mice; Mice, Obe | 2020 |
Highly bioavailable berberine formulation ameliorates diabetic nephropathy through the inhibition of glomerular mesangial matrix expansion and the activation of autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Berberine; Diabetes Mellitus, Experimental; Diabe | 2020 |
Protective effect of Berberine on reproductive function and spermatogenesis in diabetic rats via inhibition of ROS/JAK2/NFκB pathway.
Topics: Animals; Apoptosis; Berberine; Diabetes Mellitus, Experimental; Infertility, Male; Janus Kinase 2; M | 2020 |
Combination of metformin and berberine represses the apoptosis of sebocytes in high-fat diet-induced diabetic hamsters and an insulin-treated human cell line.
Topics: Animals; Apoptosis; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Diet, High-Fat; Dru | 2020 |
Metformin and Berberine suppress glycogenolysis by inhibiting glycogen phosphorylase and stabilizing the molecular structure of glycogen in db/db mice.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Glycogenolysis; Hypo | 2020 |
Effect of Berberine on Glycation, Aldose Reductase Activity, and Oxidative Stress in the Lenses of Streptozotocin-Induced Diabetic Rats In Vivo-A Preliminary Study.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Berberine; Diabetes Mellitus, Experimental; Down- | 2020 |
Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Berberine; Diabetes Mellitus, Experimental; | 2020 |
Xiaokeyinshui extract combination, a berberine-containing agent, exerts anti-diabetic and renal protective effects on rats in multi-target mechanisms.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Drug Delivery Systems; Drug Ther | 2020 |
The effect of co-administration of berberine, resveratrol, and glibenclamide on xenobiotic metabolizing enzyme activities in diabetic rat liver.
Topics: Animals; Antioxidants; Berberine; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP2B1; Diabetes Mellitu | 2022 |
Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance
Topics: Animals; Berberine; Cell Line; Dexamethasone; Diabetes Mellitus, Experimental; Drug Evaluation, Prec | 2020 |
Macrovascular Protecting Effects of Berberine through Anti-inflammation and Intervention of BKCa in Type 2 Diabetes Mellitus Rats.
Topics: Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Berberine; Cell Movement; Cell Proliferation; Ce | 2021 |
Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids.
Topics: Amino Acids, Aromatic; Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2020 |
Berberine promotes peri-implant osteogenesis in diabetic rats by ROS-mediated IRS-1 pathway.
Topics: Animals; Antioxidants; Berberine; Bone-Anchored Prosthesis; Cell Proliferation; Cells, Cultured; Dia | 2021 |
Berberine accelerated wound healing by restoring TrxR1/JNK in diabetes.
Topics: Administration, Topical; Animals; Berberine; Cell Proliferation; Diabetes Mellitus, Experimental; Di | 2021 |
Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Blood Glucose; Diabetes Mellitus, Exper | 2021 |
Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathway.
Topics: Angiotensinogen; Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibros | 2021 |
Berberine Ameliorates Glucose Metabolism in Diabetic Rats through the alpha7 Nicotinic Acetylcholine Receptor-Related Cholinergic Anti-Inflammatory Pathway.
Topics: Acetylcholinesterase; alpha7 Nicotinic Acetylcholine Receptor; Animals; Berberine; Diabetes Mellitus | 2022 |
[Effect of berberine on insulin resistance in diabetic rats].
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insul | 2020 |
Effects of berberine on cholinesterases and monoamine oxidase activities, and antioxidant status in the brain of streptozotocin (STZ)-induced diabetic rats.
Topics: Acetylcholinesterase; Animals; Antioxidants; Berberine; Blood Glucose; Brain; Butyrylcholinesterase; | 2021 |
Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway.
Topics: Amyloid beta-Peptides; Animals; Berberine; Cell Line, Tumor; Cognitive Dysfunction; Diabetes Mellitu | 2021 |
Berberine prevents diabetic retinopathy through inhibiting HIF-1α /VEGF/ NF-κ B pathway in db/db mice.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Hyperglyce | 2021 |
Berberine modulates crucial erectogenic biomolecules and alters histological architecture in penile tissues of diabetic rats.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Erectile Dysfunction; Humans; Male; Molecular D | 2021 |
In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Computational Biology; Computer Simulation; Diabetes | 2021 |
Amphiphilic block versus random copolymer nanoparticles with reactive oxygen species responsiveness as berberine vehicles.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Hydrogen Peroxide; Nanoparticles; Rats; Reactiv | 2021 |
Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota.
Topics: Animals; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dis | 2021 |
Berberine and Ginsenoside Rb1 Ameliorate Depression-Like Behavior in Diabetic Rats.
Topics: Animals; Berberine; Blood Glucose; Depression; Diabetes Mellitus, Experimental; Diet, High-Fat; Drug | 2021 |
Pharmacokinetics of Five Alkaloids and their Metabolites in Normal and Diabetic Rats after Oral Administration of Rhizoma coptidis.
Topics: Administration, Oral; Alkaloids; Animals; Berberine; Berberine Alkaloids; Coptis; Diabetes Mellitus, | 2022 |
Effects of Berberine on Diabetes and Cognitive Impairment in an Animal Model: The Mechanisms of Action.
Topics: Animals; Apoptosis; Berberine; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diet, High-Fa | 2021 |
Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice.
Topics: Animals; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diseas | 2017 |
Berberine Alleviates Oxidative Stress in Islets of Diabetic Mice by Inhibiting miR-106b Expression and Up-Regulating SIRT1.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Islets of Langerhans; Male; Mice; Mice, Inbred | 2017 |
Berberine Improves Diabetic Encephalopathy Through the SIRT1/ER Stress Pathway in db/db Mice.
Topics: Animals; Berberine; Biomarkers; Blood Glucose; Brain Diseases; Cognition Disorders; Conditioning, Ps | 2018 |
Influence of quercetin, naringenin and berberine on glucose transporters and insulin signalling molecules in brain of streptozotocin-induced diabetic rats.
Topics: Animals; Berberine; Blood-Brain Barrier; Brain; Diabetes Mellitus, Experimental; Flavanones; Glucose | 2017 |
Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk.
Topics: Animals; Berberine; Biomarkers; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mellitus, Expe | 2017 |
Berberine chloride ameliorates oxidative stress, inflammation and apoptosis in the pancreas of Streptozotocin induced diabetic rats.
Topics: Animals; Antioxidants; Apoptosis; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Inflamm | 2017 |
Protective effect of berberine on renal fibrosis caused by diabetic nephropathy.
Topics: Actins; Animals; Berberine; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Experimental; Diabet | 2017 |
Berberine Ameliorates Diabetic Neuropathy: TRPV1 Modulation by PKC Pathway.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; | 2017 |
Adenosine monophosphate-activated protein kinase modulation by berberine attenuates mitochondrial deficits and redox imbalance in experimental diabetic neuropathy.
Topics: Adenylate Kinase; Animals; Autophagy; Berberine; Cell Line; Diabetes Mellitus, Experimental; Diabeti | 2018 |
Effects of Berberine chloride on the liver of streptozotocin-induced diabetes in albino Wistar rats.
Topics: Animals; Antioxidants; Berberine; Biomarkers; Carbohydrate Metabolism; Diabetes Mellitus, Experiment | 2018 |
The protection of resveratrol and its combination with glibenclamide, but not berberine on the diabetic hearts against reperfusion-induced arrhythmias: the role of myocardial K
Topics: Animals; Arrhythmias, Cardiac; Berberine; Diabetes Mellitus, Experimental; Dose-Response Relationshi | 2019 |
Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Male; NF-kappa B; Rats; | 2018 |
Improvement of intestinal transport, absorption and anti-diabetic efficacy of berberine by using Gelucire44/14: In vitro, in situ and in vivo studies.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Berberine; B | 2018 |
Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats.
Topics: Actins; Animals; Berberine; Blood Glucose; Cell Differentiation; Cell Proliferation; Cells, Cultured | 2018 |
Possible therapeutic potential of berberine in the treatment of STZ plus HFD-induced diabetic osteoporosis.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Berberine; Blood Glucose; Body Weight; Bone Density; Deoxyguan | 2018 |
Ameliorative effect of berberine coated bio-active nanoparticles in acetaminophen induced hepato-renal damage in diabetic rats.
Topics: Acetaminophen; Animals; Antioxidants; Berberine; Diabetes Mellitus, Experimental; Drug Carriers; Kid | 2018 |
Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability.
Topics: Administration, Oral; Animals; Berberine; Biological Availability; Chromatography, High Pressure Liq | 2018 |
Hypoglycemic Mechanism of the Berberine Organic Acid Salt under the Synergistic Effect of Intestinal Flora and Oxidative Stress.
Topics: Animals; Bacteroidetes; Berberine; Diabetes Mellitus, Experimental; Feces; Gastrointestinal Microbio | 2018 |
Berberine ameliorates diabetic neuropathic pain in a rat model: involvement of oxidative stress, inflammation, and μ-opioid receptors.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Berberine; Diabetes Mellitus, Experimental; Diabetic | 2019 |
Podoplanin mediates the renoprotective effect of berberine on diabetic kidney disease in mice.
Topics: Animals; Apoptosis; Berberine; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; H | 2019 |
Glucose consumption assay discovers coptisine with beneficial effect on diabetic mice.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; E | 2019 |
Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge.
Topics: Administration, Oral; Animals; Berberine; Caco-2 Cells; Diabetes Mellitus, Experimental; Emulsions; | 2019 |
The anti-diabetic effects and pharmacokinetic profiles of berberine in mice treated with Jiao-Tai-Wan and its compatibility.
Topics: Administration, Oral; Animals; Berberine; Cinnamomum aromaticum; Cinnamomum zeylanicum; Coptis chine | 2013 |
Berberine chloride improved synaptic plasticity in STZ induced diabetic rats.
Topics: Animals; Berberine; Body Weight; Data Interpretation, Statistical; Dentate Gyrus; Diabetes Mellitus, | 2013 |
Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of RhoA/ROCK signaling.
Topics: Acetylcysteine; Active Transport, Cell Nucleus; Animals; Anti-Inflammatory Agents; Berberine; Cells, | 2013 |
Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats.
Topics: Animals; Astrocytes; Berberine; Diabetes Mellitus, Experimental; Gliosis; Hippocampus; Male; Oxidati | 2014 |
Berberine improves neurogenic contractile response of bladder detrusor muscle in streptozotocin-induced diabetic rats.
Topics: Adenosine Triphosphate; Animals; Berberine; Carbachol; Diabetes Mellitus, Experimental; Electric Sti | 2013 |
Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dinoprostone; Disease M | 2014 |
Uncoupling protein-2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS-1E cells and in diabetic mouse islets.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Diabetes Mellitus, Experimental; Glucose; Insulin | 2014 |
Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K-Akt signaling in diabetic rats.
Topics: AMP-Activated Protein Kinases; Androstadienes; Animals; Animals, Newborn; Apoptosis; Berberine; Diab | 2014 |
The renoprotective effects of berberine via the EP4-Gαs-cAMP signaling pathway in different stages of diabetes in rats.
Topics: Animals; Berberine; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Respon | 2014 |
Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experime | 2014 |
Comparative metabolites in plasma and urine of normal and type 2 diabetic rats after oral administration of the traditional Chinese scutellaria-coptis herb couple by ultra performance liquid chromatography-tandem mass spectrometry.
Topics: Animals; Berberine; Chromatography, High Pressure Liquid; Coptis; Diabetes Mellitus, Experimental; D | 2014 |
Berberine improves kidney function in diabetic mice via AMPK activation.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cell Line; Diabetes Mellitus, Experimental; Diabe | 2014 |
Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo.
Topics: Animals; Berberine; Blood Glucose; Cardiovascular Diseases; Cricetinae; Diabetes Mellitus, Experimen | 2015 |
Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.
Topics: Active Transport, Cell Nucleus; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AM | 2015 |
Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats.
Topics: Animals; Berberine; Blood Glucose; Blotting, Western; Collagen Type IV; Cytoprotection; Diabetes Mel | 2015 |
Renoprotective effects of berberine and its potential effect on the expression of β-arrestins and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in streptozocin-diabetic nephropathy rats.
Topics: Animals; Berberine; beta-Arrestins; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nep | 2016 |
Berberine Pretreatment Confers Cardioprotection Against Ischemia-Reperfusion Injury in a Rat Model of Type 2 Diabetes.
Topics: AMP-Activated Protein Kinases; Animals; Arrhythmias, Cardiac; Berberine; Biomarkers; Blood Glucose; | 2016 |
Berberine alleviates the cerebrovascular contractility in streptozotocin-induced diabetic rats through modulation of intracellular Ca²⁺ handling in smooth muscle cells.
Topics: Animals; Berberine; Blood Glucose; Calcium; Calcium Channels, L-Type; Diabetes Mellitus, Experimenta | 2016 |
Renoprotective effect of berberine via regulating the PGE2 -EP1-Gαq-Ca(2+) signalling pathway in glomerular mesangial cells of diabetic rats.
Topics: Animals; Berberine; beta-Arrestins; Biomarkers; Calcium; Calcium Signaling; Cell Membrane; Cell Prol | 2016 |
Antidiabetic potential of polyherbal formulation DB14201: Preclinical development, safety and efficacy studies.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Berberine; Blood Glucose; Chromatography, Liquid; Curcumin; Diabe | 2017 |
Berberine enhances antidiabetic effects and attenuates untoward effects of canagliflozin in streptozotocin-induced diabetic mice.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Blood Glucose; Canagliflozin; Diabetes Mellitus, | 2016 |
Protective Effects of Berberine on Renal Injury in Streptozotocin (STZ)-Induced Diabetic Mice.
Topics: Animals; Berberine; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epit | 2016 |
[Berberine inhibits cardiac fibrosis of diabetic rats].
Topics: Animals; Berberine; Collagen Type III; Connective Tissue Growth Factor; Diabetes Mellitus, Experimen | 2016 |
Identification and Verification of Potential Therapeutic Target Genes in Berberine-Treated Zucker Diabetic Fatty Rats through Bioinformatics Analysis.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Berberine; Blood Glucose; Carbohydrate M | 2016 |
Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Area Under Curve; Berberine; Biomarkers; Blo | 2017 |
Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Chemical and Drug Induced Liver Injury; Diabetes Mel | 2008 |
Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats.
Topics: alpha-Glucosidases; Animals; Berberine; Bile Acids and Salts; Blood Glucose; Body Weight; Data Inter | 2008 |
Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase.
Topics: Aldehyde Reductase; Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Mal | 2008 |
Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.
Topics: Adenylate Kinase; Animals; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Drug Evaluat | 2009 |
Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats.
Topics: Animals; Berberine; Body Weight; Diabetes Mellitus, Experimental; Dietary Carbohydrates; Dietary Fat | 2009 |
Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin.
Topics: Animals; Berberine; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary | 2009 |
Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study.
Topics: Acarbose; Animals; Berberine; Blood Glucose; Caco-2 Cells; Cyclic AMP-Dependent Protein Kinases; Dia | 2010 |
Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats.
Topics: Adiponectin; Animals; Berberine; Blood Glucose; C-Reactive Protein; Cholesterol; Diabetes Mellitus, | 2011 |
Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Extrac | 2010 |
Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway.
Topics: Albuminuria; Animals; Berberine; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Nephro | 2010 |
Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.
Topics: Animals; Antioxidants; Berberine; Coptis; Cyclin T; Cyclin-Dependent Kinase 9; Diabetes Mellitus, Ex | 2011 |
Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes.
Topics: Acetylcholine; Administration, Oral; Analysis of Variance; Animals; Antioxidants; Ascorbic Acid; Ber | 2011 |
Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down- | 2011 |
[Antidiabetic activity of berberin and extract, obtained from the bark of Phellodendron lavalei, introduced in subtropic regions of Georgia, in streptozotocin induced diabetic rats].
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Georgia (Republic); Hypoglycemic | 2011 |
[Changes of metabolic indices caused by berberin and extract, obtained from the bark of Phellodendron lavalei, introduced in subtropic regions of Georgia, in streptozotocin induced diabetic rats].
Topics: Animals; Berberine; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Georgia (Republic); | 2011 |
Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway.
Topics: Animals; Berberine; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Glucokinase; | 2011 |
Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine.
Topics: Administration, Oral; Animals; Berberine; Biological Availability; Blood Glucose; Crystallization; D | 2011 |
Berberine alleviates ischemic arrhythmias via recovering depressed I(to) and I(Ca) currents in diabetic rats.
Topics: Administration, Oral; Animals; Arrhythmias, Cardiac; Berberine; Calcium; Calcium Channels, L-Type; C | 2012 |
[Effect of berberine on expression of transforming growth factor-beta1 and type IV collagen proteins in mesangial cells of diabetic rats with nephropathy].
Topics: Animals; Berberine; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene | 2011 |
Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cholesterol; Creatinine; Diabetes Mellitus, Experime | 2012 |
Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis.
Topics: Adenylate Kinase; Animals; Area Under Curve; Berberine; Blood Glucose; Decanoic Acids; Diabetes Mell | 2012 |
Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Fibron | 2012 |
Anti-hyperglycemic effects and mechanism of traditional Chinese medicine Huanglian Wan in streptozocin-induced diabetic rats.
Topics: alpha-Glucosidases; Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Glycoside Hy | 2012 |
Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking.
Topics: Alkaloids; Animals; Berberine; Blood Glucose; Castanospermum; Diabetes Mellitus, Experimental; Diabe | 2012 |
Hippocampal synaptic plasticity restoration and anti-apoptotic effect underlie berberine improvement of learning and memory in streptozotocin-diabetic rats.
Topics: Administration, Oral; Animals; Apoptosis; Avoidance Learning; Berberine; CA1 Region, Hippocampal; De | 2013 |
Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cyclic AMP; Diabetes Mellitus, Experimental; Diabeti | 2013 |
Berberine ameliorates renal injury by regulating G proteins-AC- cAMP signaling in diabetic rats with nephropathy.
Topics: Adenylyl Cyclases; Animals; Berberine; Blood Glucose; Cell Proliferation; Collagen Type IV; Connecti | 2013 |
Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion.
Topics: Animals; Berberine; Blood Glucose; Cells, Cultured; Cholesterol; Cholesterol, HDL; Cricetinae; Diabe | 2004 |
Hypoglycemic activity of jatrorrhizine.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Glycolysis; Hypoglycemic Agents; L-Lactate Dehy | 2005 |
Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats.
Topics: Alloxan; Animals; Berberine; Blood Glucose; Coptis; Diabetes Mellitus, Experimental; Dietary Fats; D | 2006 |
Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy | 2007 |
Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose.
Topics: Aldehyde Reductase; Animals; Berberine; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Expe | 2008 |
[Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research].
Topics: Adult; Aged; Alloxan; Animals; Berberine; Berberine Alkaloids; Blood Glucose; Diabetes Mellitus, Exp | 1988 |
[Studies on the hypoglycemic effect of Coptis chinensis and berberine].
Topics: Animals; Berberine; Berberine Alkaloids; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental | 1986 |